SLC5A2 and hydrops fetalis: Even though treatments like SGLT2 inhibitors emerged as promising tools for HF across the EF spectrum and regardless of body weight [17], including GLP‐1 RAs in the therapeutic regimen in those individuals with obesity could offer a complementary strategy for the management of HFpEF.